Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer.[6] Ribociclib is a kinase inhibitor.[7][8] It was developed by Novartis and Astex Pharmaceuticals.[9]
The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash.[5]
Ribociclib was approved by the US Food and Drug Administration (FDA) in March 2017,[10][11] by the European Medicines Agency (EMA) in August 2017,[5][12] and for use in the National Health Service (NHS) by National Institute for Health and Care Excellence (NICE) in February 2021.[7][13]
^"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^"Search Page - Drug and Health Product Register". 23 October 2014.
^"Kisqali- ribociclib tablet, film coated". DailyMed. 4 May 2023. Retrieved 9 July 2023.
^ abc"Kisqali EPAR". European Medicines Agency (EMA). 31 March 2023. Retrieved 9 July 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^FDA Professional Drug Information on Kisqali. Accessed 8 September 2017.
^ ab"Thousands of breast cancer patients to have routine access to NICE-approved drug combination". NICE (Press release). Retrieved 8 March 2021.
^"Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.
^"Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer" (Press release). Novartis. 1 November 2016.
^"Kisqali (ribociclib) Tablets". U.S. Food and Drug Administration (FDA). 28 March 2017. Retrieved 9 July 2023.
^"FDA Clears Novartis Kisqali for Combination Breast Cancer Therapy". Genetic Engineering and Biotechnology News. 14 March 2017. Retrieved 9 July 2023.
^"Kisqali: EPAR – Product Information" (PDF). European Medicines Agency. 31 August 2017.
^"Life-extending drug for incurable breast cancer approved for NHS use". The Guardian. 26 February 2021. Retrieved 8 March 2021.
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor...
FDA approved, but several compounds are in clinical trials. See also Ribociclib#Mechanism of action re: CDK4 The cell cycle is a highly regulated process...
approved ribociclib, owned by Novartis, as a combination therapy with aromatase inhibitors for indications similar to those of palbociclib and ribociclib. Notably...
shown in a study with rifampicin. Like the related drugs palbociclib and ribociclib, abemaciclib inhibits the enzymes cyclin-dependent kinase 4 (CDK4) and...
fulvestrant, often used in combination with CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib). When one endocrine therapy fails, most will benefit...
for anti-tumor effectiveness. Three Cdk4/6 inhibitors – palbociclib, ribociclib, and abemaciclib – currently received FDA approval for clinical use to...
Jakavi/Jakafi (ruxolitinib) Myelofibrosis (of intermediate to high risk) Kisqali (ribociclib) Breast Cancer 1,231 2022 Kymriah (tisagenlecleucel) Acute lymphoblastic...
PMC 5571795. PMID 28875019. Tripathy D, Bardia A, Sellers WR (July 2017). "Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent...
Global Information
